Akero Therapeutics (AKRO) News Today $54.90 -0.50 (-0.90%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$54.59 -0.31 (-0.57%) As of 09:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AKRO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period GAMMA Investing LLC Grows Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)GAMMA Investing LLC boosted its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 8,057.1% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 10,849 shares of the company's stock after buying an additional 10,716 shares during the pJune 20 at 3:13 AM | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Given Average Rating of "Buy" by AnalystsShares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) have been assigned an average recommendation of "Buy" from the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation.June 19 at 4:43 AM | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Trading Down 3.3% - Here's What HappenedAkero Therapeutics (NASDAQ:AKRO) Trading Down 3.3% - What's Next?June 16, 2025 | marketbeat.comRhumbline Advisers Purchases 5,001 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)Rhumbline Advisers boosted its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 4.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 110,687 shares of the company's stock after buying anJune 14, 2025 | marketbeat.comJefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t PleasedJune 13, 2025 | msn.comPatrick Lamy Sells 919 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockJune 13, 2025 | insidertrades.comInsider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells 919 Shares of StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) VP Patrick Lamy sold 919 shares of the firm's stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $54.00, for a total transaction of $49,626.00. Following the transaction, the vice president now directly owns 32,573 shares of the company's stock, valued at $1,758,942. The trade was a 2.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.June 12, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Insider Timothy Rolph Sells 2,358 SharesAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 2,358 shares of the company's stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $54.00, for a total transaction of $127,332.00. Following the completion of the sale, the insider now directly owns 167,363 shares in the company, valued at $9,037,602. This represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.June 12, 2025 | marketbeat.comInsider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells 2,493 Shares of StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) COO Jonathan Young sold 2,493 shares of the firm's stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $53.99, for a total transaction of $134,597.07. Following the transaction, the chief operating officer now directly owns 198,047 shares of the company's stock, valued at $10,692,557.53. The trade was a 1.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.June 12, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 2,803 SharesAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Catriona Yale sold 2,803 shares of the stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $54.00, for a total transaction of $151,362.00. Following the sale, the insider now directly owns 92,231 shares in the company, valued at $4,980,474. This trade represents a 2.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.June 12, 2025 | marketbeat.comWilliam Richard White Sells 2,804 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) CFO William Richard White sold 2,804 shares of Akero Therapeutics stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $53.99, for a total value of $151,387.96. Following the sale, the chief financial officer now owns 59,155 shares in the company, valued at $3,193,778.45. This represents a 4.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.June 12, 2025 | marketbeat.comAndrew Cheng Sells 37,837 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) CEO Andrew Cheng sold 37,837 shares of Akero Therapeutics stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $54.05, for a total value of $2,045,089.85. Following the transaction, the chief executive officer now directly owns 556,487 shares in the company, valued at approximately $30,078,122.35. The trade was a 6.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.June 12, 2025 | marketbeat.comAkero Therapeutics Target of Unusually High Options Trading (NASDAQ:AKRO)June 11, 2025 | americanbankingnews.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Stake Raised by SG Americas Securities LLCSG Americas Securities LLC lifted its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 93.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,155,787 shares of the company's stock afJune 10, 2025 | marketbeat.comInsider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 12,500 Shares of StockJune 10, 2025 | insidertrades.comMillennium Management LLC Sells 57,892 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)Millennium Management LLC lessened its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 77.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,736 shares of thJune 10, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Insider Timothy Rolph Sells 12,500 SharesAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 12,500 shares of the stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $53.49, for a total value of $668,625.00. Following the transaction, the insider now owns 169,721 shares of the company's stock, valued at $9,078,376.29. The trade was a 6.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.June 9, 2025 | marketbeat.comInsider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 25,000 Shares of StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 25,000 shares of Akero Therapeutics stock in a transaction on Friday, June 6th. The shares were sold at an average price of $55.04, for a total value of $1,376,000.00. Following the completion of the sale, the insider now owns 169,721 shares in the company, valued at $9,341,443.84. This represents a 12.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.June 9, 2025 | marketbeat.comInvestors Buy High Volume of Akero Therapeutics Call Options (NASDAQ:AKRO)Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) was the target of some unusual options trading activity on Monday. Investors bought 3,105 call options on the company. This represents an increase of approximately 106% compared to the average volume of 1,508 call options.June 9, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 18.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund ownJune 8, 2025 | marketbeat.comPatrick Lamy Sells 4,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) VP Patrick Lamy sold 4,000 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $50.31, for a total transaction of $201,240.00. Following the completion of the transaction, the vice president now directly owns 33,492 shares of the company's stock, valued at approximately $1,684,982.52. The trade was a 10.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.June 5, 2025 | marketbeat.comInsider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells 4,000 Shares of StockJune 5, 2025 | insidertrades.comAmeriprise Financial Inc. Makes New Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO)Ameriprise Financial Inc. bought a new position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 15,172 shares of the company's stock, valued at approxJune 5, 2025 | marketbeat.comBank of America Corp DE Has $1.84 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)Bank of America Corp DE cut its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 58.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 66,264 shares of the company's stock after selling 93,294 sharJune 4, 2025 | marketbeat.comAkero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 3, 2025 | globenewswire.comTwo Sigma Advisers LP Acquires 27,200 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)Two Sigma Advisers LP lifted its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 195.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,100 shares of the company's stock after acquirinJune 1, 2025 | marketbeat.comTwo Sigma Investments LP Increases Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO)Two Sigma Investments LP boosted its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 43.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 127,320 shares of the compaMay 31, 2025 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Trading 4.5% Higher - Should You Buy?Akero Therapeutics (NASDAQ:AKRO) Stock Price Up 4.5% - What's Next?May 30, 2025 | marketbeat.comBNP Paribas Financial Markets Sells 12,220 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)BNP Paribas Financial Markets decreased its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 59.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,482 shares of the company'May 30, 2025 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Price Target Raised to $64.00 at Bank of AmericaBank of America boosted their price objective on Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research report on Tuesday.May 28, 2025 | marketbeat.comAkero Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Shares Acquired by ProShare Advisors LLCProShare Advisors LLC lifted its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 32.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 22,398 shares of the company's stock after buying an additional 5,May 27, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Decreases Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)D. E. Shaw & Co. Inc. lessened its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 71.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,809 shares of the company's stock afterMay 26, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Receives Consensus Rating of "Buy" from BrokeragesShares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) have been assigned an average recommendation of "Buy" from the eight analysts that are currently covering the stock, MarketBeat reports. Eight analysts have rated the stock with a buy rating. The average 1 year price target among bMay 26, 2025 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Stock Price Down 5.9% - Here's What HappenedAkero Therapeutics (NASDAQ:AKRO) Stock Price Down 5.9% - Here's WhyMay 25, 2025 | marketbeat.comWoodline Partners LP Boosts Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)Woodline Partners LP lifted its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 29.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 379,967 shares of the company's stock after purchasing an additional 87,499 shares duriMay 25, 2025 | marketbeat.comRafferty Asset Management LLC Sells 17,797 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)Rafferty Asset Management LLC reduced its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 19.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 72,604 shares of the company's stock after selling 1May 23, 2025 | marketbeat.comAkero: FGF21 Advancement For MASH Targeting Presses On With Key DevelopmentsMay 21, 2025 | seekingalpha.comWhy Akero Therapeutics, Inc. (AKRO) Skyrocketed TodayMay 21, 2025 | msn.comAkero surges after report on plans for potential saleMay 20, 2025 | msn.com32,150 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Purchased by Tema Etfs LLCTema Etfs LLC acquired a new stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 32,150 shares of the company's stock, valued at approximately $894,000. SeveralMay 20, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Holdings Reduced by Deutsche Bank AGDeutsche Bank AG lessened its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 18.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 273,811 shares of the company's stockMay 20, 2025 | marketbeat.comPoint72 Asset Management L.P. Sells 403,643 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)Point72 Asset Management L.P. reduced its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 31.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 899,680 shares of the company's stock afteMay 19, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Shares Bought by RTW Investments LPRTW Investments LP raised its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 15.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,859,823 shares of the company's sMay 18, 2025 | marketbeat.com30,208 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Bought by Cubist Systematic Strategies LLCCubist Systematic Strategies LLC bought a new position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 30,208 shares of the company's stock, valued at approximately $840,000. A number of other iMay 17, 2025 | marketbeat.comNorthern Trust Corp Increases Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)Northern Trust Corp grew its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 6.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 620,321 shares of the company's stock after buying an additional 35,737May 17, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Shares Bought by MPM Bioimpact LLCMPM Bioimpact LLC raised its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 17.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 460,617 shares of the company's stock after purchasing an additionaMay 16, 2025 | marketbeat.com66,000 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Purchased by Orbimed Advisors LLCOrbimed Advisors LLC acquired a new stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 66,000 shares of the company's stock, valuedMay 15, 2025 | marketbeat.comJanus Henderson Group PLC Sells 1,043,239 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)Janus Henderson Group PLC trimmed its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 14.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,034,239 shares of the company's stock aftMay 15, 2025 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Posts Earnings Results, Beats Estimates By $1.90 EPSAkero Therapeutics (NASDAQ:AKRO - Get Free Report) posted its earnings results on Monday. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of ($1.00) by $1.90.May 14, 2025 | marketbeat.com Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address AKRO Media Mentions By Week AKRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKRO News Sentiment▼1.130.68▲Average Medical News Sentiment AKRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKRO Articles This Week▼57▲AKRO Articles Average Week Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Summit Therapeutics News Genmab A/S News Intra-Cellular Therapies News Dr. Reddy's Laboratories News Ascendis Pharma A/S News Viatris News Qiagen News Moderna News Blueprint Medicines News BridgeBio Pharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKRO) was last updated on 6/20/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… and it's all thanks to President Trump. His administr...InvestorPlace | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | SponsoredWar-Proof Power Why This "Weird" Government Land Auction Was No Ordinary Sale When 218,000 acres of land... smack in the m...Stansberry Research | Sponsored50-year legend: Here’s exact day stocks will crashGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AKRO Stock Free AKRO Stock Alerts